Deal overview

Deal overview
Target DAIICHI SANKYO (CERTAIN RIGHTS TO TRASTUZUMAB DERUXTECAN)
Bidder ASTRAZENECA PLC
Price £60.00 Full version or £25.00 Light version
Publication Date Mar 28, 2019
Abstract On 28 March 2019[+], it was announced that the UK quoted pharmaceuticals group AstraZeneca Plc, had entered into a global development and commercialisation collaboration agreement with the Japanese quoted pharmaceuticals group Daiichi Sankyo Company, Limited ("Daiichi Sankyo") for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate ("ADC") and potential ...
Number of pages (Full version) 6
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Search for Deals

Search over 70 million deal reports on more than 550,000 public and private companies. (copy)

Back to search results

Page Time: 0.024762s